Study identifier:D1950C00013
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase I, Single Centre, Double-blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Modified-Release Formulations of AZD1446 in Young and Elderly Healthy Japanese volunteers after oral Single and Repeated Doses
Healthy
Phase 1
Yes
AZD1446, Placebo
All
24
Interventional
20 Years - 80 Years
Allocation: Randomized 
Endpoint Classification: Safety Study 
Intervention Model: Parallel Assignment 
Masking: Double Blind 
Primary Purpose: Basic Science 
Verified 01 Jul 2014 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
No locations available
| Arms | Assigned Interventions | 
|---|---|
| Experimental: 1 Oral capsule. Dose single and followed by 5-day repeated dosing. Specific doses depend on panel.  | Drug: AZD1446  oral capsule, Moderate Release  | 
| Placebo Comparator: 2 Oral capsule. Dose single and followed by 5-day repeated dosing.  | Drug: Placebo  oral capsule Other Name: Placebo  |